1. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy 
L. Santos Filho, K.J. Eagye, J.L. Kuti, D.P. Nicolau 
Clinical Microbiology and Infection 
Volume 13, Issue 6, Pages (June 2007)
DOI: /j x
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Distribution of MICs for 208 isolates of Pseudomonas aeruginosa, displayed as a percentage of total isolates.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2
Probability of bactericidal target attainment using various regimens of meropenem, with a target of 40% fT>MIC (INF, infusion; q8h, every 8 h; PTA, probability of target attainment).
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

4. FIG. 3
Probability of bacteriostatic target attainment using various regimens of meropenem against Pseudomonas aeruginosa with a target of 20% fT>MIC (INF, infusion; q8h, every 8 h; PTA, probability of target attainment).
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

5. FIG. 4
Probability of target attainment (PTA) of various meropenem regimens when the target is a CMIN/MIC of ≥6.2 (INF, infusion; q8h, every 8 h).
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

6. FIG. 5
Probability of target attainment (PTA) of various regimens of meropenem when the target is a CMIN/MIC of ≥1.7 (INF, infusion; q8h, every 8 h).
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions